Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: Evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy

Journal of Viral Hepatitis

Volumn 5, Issue 5, 1998, Pages 307-312

  Honkoop, P ^a   De Man, R A ^a,b   Niesters, H G M ^b   Main, J ^c   Nevens, F ^d   Thomas, H C ^c   Fevery, J ^d   Tyrrell, D L ^e   Schalm, S W ^a  

^a Department of Hepatogastroenterology ^*  (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ST MARY S HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antiviral therapy; Chronic hepatitis; Hepatitis B; Lamivudine; Nucleoside analogues; Polymerase chain reaction

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOSINE DERIVATIVE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS; SINGLE-BLIND METHOD; TIME FACTORS;

EID: 0031680051     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1998.00121.x     Document Type: Article

References (19)

1. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991; 88: 8495-8499.
2. Kruining J, Heijtink RA, Schalm SW. Antiviral agents in hepatitis B virus transfected cell lines: inhibitory and cytotoxic effect related to time of treatment. J Hepatol 1995; 22: 263-267.
3. Tyrrell DLJ, Fischer K, Savani K, Tan W, Jewell L. Treatment of chimpanzees and ducks with lamivudine (2′,3′-dideoxy-3′ thiacytidine) results in rapid suppression of hepaviral DNA in sera (abstr). Clin Invest Med 1993; 16: (suppl 4): B77.
4. Dienstag JL, Perrillo RP, Schiff ER. Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657-1661.
5. Nevens F, Main J, Honkoop P et al. Lamivudine therapy for chronic hepatitis B. A six months randomized dose ranging study. Gastroenterology 1997; 113: 1258-1263.
6. Zaaijer HL, ter Borg F, Cuypers HT, Hermus MC, Lelie PN. Comparison of methods for detection of hepatitis B virus DNA. J Clin Microbiol 1994; 32: 2088-2091.
7. Quint WG, Heijtink RA, Schirm J, Gerlich WH, Niesters HG. Reliability of methods for hepatitis B virus DNA detection. J Clin Microbiol 1995; 33: 225-228.
8. Kuhns MC, McNamara AL, Cabal CM et al. A new assay for the quantitative detection of hepatitis B viral DNA in human serum. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. New York: AR Liss Inc., 1988: 258-262.
9. Janssen HL, Schoenmaker-Weber YA, Kruining H, Schalm SW, Heijtink RA. Quantitative assessment of hepatitis B virus DNA in chronic hepatitis B. Comparison of two solution hybridization assays. J Med Virol 1993; 40: 307-312.
10. Boom R, Sol CJ, Heijtink R, Wertheim-van Dillen PM, van der Noordaa J. Rapid purification of hepatitis B virus DNA from serum. J Clin Microbiol 1991; 29: 1804-1811.
11. Gerlich WH, Heermann KH, Thomssen R and the Eurohep group. Quantitation assays for hepatitis B virus DNA. standardisation and quality control. Viral Hep Rev 1995; 1: 53-57.
12. Honkoop P, de Man RA. Scholte HR et al. Effect of lamivudine treatment on morphology and function of the mitochondria in patients with chronic hepatitis B. Hepatology 1997; 26: 211-215.
13. Honkoop P, de Man RA, Zondervan PE, Schalm SVV. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver 1997; 17: 103-106.
14. Bartholomew MM, Jansen RW, Jeffers LJ et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20-22.
15. Honkoop P, Niesters HGM, de Man RA, Osterhaus ADME, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B incidence patterns. J Hepatol 1997; 26: 1393-1395.
16. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847.
17. O'Grady JG, Smith HM, Davies SE et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992; 14: 104-111.
18. Lucey M. Hepatitis B infection and liver transplantation: the art of the impossible. Hepatology 1994; 19: 245-247.
19. Grellier L, Mutimer D, Ahmed M et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212-1215.